Viking Therapeutics Inc

NASDAQ:VKTXUnited States

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for metabolic and endocrine disorders. The Company's lead clinical program's drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRb). The Company is conducting VOYAGE study, a phase II b clinical trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). It is also developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is engaged in a phase I b clinical trial of VK0214 in patients with X-ALD. The Company’s other clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator (SARM).

Contact Information

Headquarters

9920 Pacific Heights Blvd, Suite 350SAN DIEGO, CA, United States 92121

Phone

858-704-4660

Fax

302-636-5454

Executives

Independent Chairman of the Board

Lawson Macartney

President, Chief Executive Officer, Director

Brian Lian

Chief Financial Officer

Greg Zante

Chief Operating Officer

Marianne Mancini

Independent Director

Matthew Foehr